W.R. Berkley Corp’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

W.R. Berkley Corp’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-49,060	Closed	-$488K	–	584
2021 Q3	$488K	Buy	49,060 +24,212	+97%	+$240K	0.03%	340
2021 Q2	$247K	Hold	24,848	–	–	0.02%	307
2021 Q1	$247K	Buy	+24,848	New	+$265K	0.03%	267

Other funds holding STLN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

PGM

Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

W.R. Berkley Corp's STLN Position: Q4 2021 in Review

W.R. Berkley Corp sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q4 2021, closing a stake of 49,060 shares — an estimated $488K sold.

W.R. Berkley Corp first reported a position in STLN in Q1 2021 and held it in 3 quarters. The position peaked at $488K in Q3 2021. 21 funds tracked by Wall St. Rank hold STLN as of Q4 2021.

W.R. Berkley Corp reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
W.R. Berkley Corp sold 49,060 Starling Oncology Institute, Inc. Common Stock shares in Q4 2021, an estimated $488K.
W.R. Berkley Corp first reported a position in Starling Oncology Institute, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
W.R. Berkley Corp's Starling Oncology Institute, Inc. Common Stock position peaked at $488K in Q3 2021.
21 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q4 2021.

Based on W.R. Berkley Corp's 13F filing for Q4 2021, filed 14 Feb 2022.